Dear Friends,

This year, the GI Research Foundation made its most significant investments ever in critical research with the potential to transform lives.

At just 14 years old, my daughter Sydney was diagnosed with Crohn’s disease. I quickly learned that research was crucial in developing better treatments and finding a cure for Sydney. She inspired me to join the Board of Directors and actively participate in her long-term health and happiness.

My Board experience gave me a deeper understanding of the countless individuals struggling with many digestive diseases. Sydney continues to inspire me, as do the millions of children and adults longing for better health.

On behalf of the Board of Directors, our renowned Scientific Advisors, and exceptional partners at the University of Chicago Medicine Digestive Diseases Center—thank you for your support. You help make life-transforming research possible.

KATHRYN KARMIN SHAFER
President, Board of Directors
Because you believed in us, the GI Research Foundation’s funding drove many important discoveries:

- The first gene associated with Crohn’s disease (NOD2)
- How genetic and environmental risk factors impact colorectal cancer development
- The cause of ulcerative colitis
- The first living donor liver transplant from parent to child
- Immune factors related to celiac disease
- The first animal model of celiac disease
- International clinical trials which led to a cure for Hepatitis C

Continued funding is driving more and more transformative discoveries to improve lives.
DIGESTIVE DISEASES: FROM ABDOMINAL ADHESIONS TO ZOLLINGER-ELLISON SYNDROME

SIXTY TO SEVENTY MILLION AMERICANS LIVE WITH A DIGESTIVE DISEASE, ENDURING DAILY DISTRESS, DEBILITATING PAIN, AND FATAL OUTCOMES. THE GI RESEARCH FOUNDATION PROUDLY PARTNERS WITH THE RENOWNED UNIVERSITY OF CHICAGO MEDICINE DIGESTIVE DISEASES CENTER TO TRANSFORM THEIR LIVES.

IMPACT OF YOUR SUPPORT: WE HAVE INVESTED TENS OF MILLIONS OF DOLLARS IN RESEARCH

$25.7 MILLION in the past five years.

<table>
<thead>
<tr>
<th>Fiscal Year (Date End)</th>
<th>Total Research Investment</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>$1,376,612</td>
</tr>
<tr>
<td>2020</td>
<td>$1,337,497</td>
</tr>
<tr>
<td>2021</td>
<td>$1,239,877</td>
</tr>
<tr>
<td>2022</td>
<td>$1,525,364</td>
</tr>
<tr>
<td>2023</td>
<td>$20,219,690</td>
</tr>
</tbody>
</table>

ABDOMINAL ADHESIONS • ACHALASIA • ACID REFLUX • ALCOHOLIC LIVER DISEASE • ALPHA-1 ANTITRYPSIN DEFICIENCY • ANAL CANCER • APPENDICITIS • APPENDIX CANCER • BARIATRIC SURGERY • BARRETT’S ESOPHAGUS • BILE DUCT CANCER • CELIAC DISEASE • CIRRHOSIS • COLON POLYPS • COLORECTAL CANCER • CONDYLOMA • CONSTIPATION • CROHN’S DISEASE • CYCLIC VOMITING SYNDROME • DIARRHEA • DIVERTICULITIS • DIVERTICULOSIS • DUMPLING SYNDROME • DYSPESIA • ESOPHAGEAL CANCER • EXOCRINE PANCREATIC INSUFFICIENCY • FATTY LIVER DISEASE • FIBROLAMELLAR CANCER • FISSURES • FISTULAS • FOOD POISONING • GALLBLADDER CANCER • GALLSTONES • GASTRITIS • GASTROINTESTINAL BLEEDING • GASTROINTESTINAL CANCERS • GASTROPARESIS • HEMOCHROMATOSIS • HEMORRHOIDS • HEPATITIS • HEPATOBLASTOMA • HEPATOMEGALIC CARCINOMA • HIRSCHSPRUNG DISEASE • INTESTIVIGATION • INGUINAL Hernia • INTESTINAL FAILURE • INTESTINAL PSEUDO-OBSTUCTION • IRRITABLE BOWEL SYNDROME • LACTOSE INTOLERANCE • LARGE COLON POLYPS • LIVER CANCER • LIVER DISEASE • LIVER FAILURE • LIVER TRANSPLANT • MEDICAL WEIGHT LOSS • MICROSCOPIC COLITIS • NEUROENDOCRINE TUMORS • PANCREATITIS • PANCREATIC CANCER • PANCREATIC DISEASES • PERIANAL ABSCESS • PILONIDAL DISEASE • PRIMARY BILIARY CHolangitis • PRIMARY SCLEROSING CHolangitis • PROCTITIS • PRURITIS ANI • RECTAL PROLAPSE • SHORT BOWEL SYNDROME • SMALL BOWEL BLEEDING • STOMACH CANCER • SWALLOWING DISORDERS • ULCERATIVE COLITIS • VIRAL GASTROENTERITIS • WILSON’S DISEASE • ZOLLINGER-ELLISON SYNDROME
Colorectal cancer (CRC) recurs in about 30% of patients, almost always with fatal consequences. Advancing the understanding of the connection between diet, bile acids and colorectal cancer recurrence could help prevent it and save lives.

Dr. Li has recently discovered that acetate produced from gut bacteria helps prevent colon epithelial aging, which may point to a new therapeutic approach for IBD.

Celiac disease (CeD) is an inflammatory disorder caused by eating gluten. Because only a small percentage of genetically susceptible individuals develop CeD, other environmental factors may contribute. This study investigates if the gut microbiota contributes to the development of CeD.

Think of your gut microbiome as a garden. To flourish it needs good soil. Using a multidisciplinary approach to understand and optimize the use of soil-inspired materials (the foundation in and on which to health gut bacteria can grow and thrive) for balancing the gut microbiota, this award seeks to improve overall human health.

"Having a digestive disease—any one of them—disrupts your life and is incredibly scary. Like every digestive disease patient I know, I live with the fear of 'what if'. What if my current treatment fails? What if I need surgery? What if I get cancer because I am at greater risk? Research outcomes are how we can stop asking.”

Jen Riback, patient and mother of two patients
WE INVESTED IN DYNAMIC RESEARCH ACROSS THE DIGESTIVE DISEASES SPECTRUM Funding by-invitation grants as identified by our Scientific Advisors throughout the fiscal year.

DAVID T. RUBIN, MD
ASHLEY SIDEBOTTOM, PHD
$100,000
Exploring the Gut Inflammation’s Impact on Anxiety and Depression in IBD Patients

Patients with inflammatory bowel disease (IBD) have an increased risk of anxiety and depression. This award supports the study of biological explanations for the connection between IBD and anxiety and depression.

CAMBRIAN LIU, PHD
$100,000
Reprogramming Stem Cells to Treat IBD

Regenerative medicine is the process of replacing or “regenerating” human cells, tissues, or organs to restore or establish normal function. Dr. Liu is continuing to work to develop new methods of identifying and reprogramming stem cells as treatments for inflammatory bowel disease (IBD).

“If we can explain that anxiety and depression in IBD are biological, it would revolutionize our understanding of these co-existing conditions, provide new ways to predict or screen for them, destigmatize the mood disorders, and help us to markedly improve the quality of life of these individuals.”
David T. Rubin, MD

“You could use these cells as a Band-Aid. You could cover up areas of bleeding in these patients so that you can tilt the balance back toward healing. In patients that have really severe disease, [it may even be possible to] rebuild a good portion of the lining of the intestine with these stem cells.”
Cambrion Liu, PhD

EDWIN MCDONALD, MD
$75,000
Community Health in Digestive Diseases

In 2022, UChicago Medicine Digestive Diseases Center established and launched a multifaceted program to improve the health of residents on the South Side of Chicago, who are disproportionately affected by chronic disease. The study, which just completed its second of three years of funding, examines the effectiveness of food and nutrition intervention on the composition of individual patient’s microbiome.

JUN HUANG, PHD
$150,000
Early Development of Immunotherapy for Inflammatory Bowel Disease

This study lays the groundwork for a new immunotherapy for inflammatory bowel disease (IBD). Because existing biologic therapies can lose effectiveness or fail over time, discovering a new immunotherapy using the body’s immune system to correct the imbalance found in IBD could be a game-changer.

CHRISTOPHER WEBER, MD, PHD
LE SHEN, MB, PHD
$100,000
Development of Colorectal Organoid Models to Facilitate Better Patient Care

Organoids are three-dimensional tissue cultures that can be grown quickly and inexpensively from human specimens collected during routine diagnostic procedures. The study of organoids offers potential benefits in the understanding and treatment of cancer and digestive diseases. This study investigates how often organoids are predictive of tumor response in colorectal cancer patients.
WE LAUNCHED CA CURE
A bold initiative designed to advance treatments and find cures for gastrointestinal cancers—made possible by an anonymous donor’s transformational gift.

**Elicio Therapeutics**
$2,756,000
Development of a Lymph Node Targeting Vaccine for Patients with BRAFV600E and TP53 R248W Tumor Neoantigens
This project seeks to develop two therapeutic cancer vaccines. Both vaccines have been designed with Elicio’s proprietary lymph node targeting Amphiphile (AMP) platform that “educates” T cells on how to target particular antigens, such as mutated proteins in cancer.

**Weill Cornell Medicine**
$833,515
Colorectal Cancer (CRC) Cellular Heterogeneity, Metastasis, and a Spatially Resolved Molecular Atlas for the Colon
Funding supports research utilizing a cutting-edge, sub-cellular spatial profiling technology to reveal novel aspects of colorectal cancer (CRC) heterogeneity and improve our understanding of normal tissues, at both the RNA and protein levels.

**MD Anderson Cancer Center**
$3,519,021
Advanced Approaches to Understanding and Targeting BRAF Tumors
Three interrelated projects designed to improve survival in patients with BRAF-mutated (BRAFmut) colorectal cancer (CRC).

**University of Iowa**
$1,698,949
Advanced Approaches to Understanding and Targeting BRAF Tumors
This project tests the effect of combining specific drugs to target colorectal cancer cells that have rare combinations of multiple mutations and are resistant to standard therapies.

**RareCyte, Inc.**
$900,000
CTC Sample Collection, Processing and Biomarker Testing
Testing gastrointestinal cancer patient samples within clinical trials to determine circulating tumor cell (CTC) burden and selected biomarker analysis. The emerging trend of personalized medicine (patient specific therapy) requires deeper understanding of the makeup of CTCs, both at the protein and gene level, to select therapies which specifically treat the individual patient’s cancer.

**Mayo Clinic**
$5,942,244
Novel Individualized Therapeutic Strategies for Metastatic Colorectal Cancer
This project proposes three different strategies to enhance survival and potentially cure cancer—optimization of the immune system, activation of the immune system to combat cancer, novel combination therapies. Two strategies are in the human clinical trial phase, and one is in the discovery phase.

**Yale School of Medicine with UChicago Medicine**
$1,382,041
Development of SHMC Based Plasma Signatures (Liquid Biopsy) in the Detection of Patients with Peritoneal Metastases
Cancers of the colon, rectum, and appendix can spread to the lining of the abdominal cavity and are difficult to detect. This project, a collaboration with UChicago Medicine, uses the novel approaches of DNA measurement through liquid biopsy to detect these cancers early.

**Hoosier Cancer Research Network**
$1,100,000
A Single Arm Phase II Study with Safety Run-In of Peptide Receptor Radionuclide Therapy in Combination with Immunotherapy for Patients with Merkel Cell Cancer
Supports the first of its kind clinical trial looking at a novel area of therapy treating cancer called THERANOSTICS (therapy + diagnostics).

**Weill Cornell Medicine**
$290,000
Capturing Circulating Tumor Cells as Liquid Biopsies for Patients with Advanced/Metastatic Colorectal Cancer and Other Malignancies
Liquid biopsies are revolutionizing cancer care. This project focuses on circulating tumor cells (CTCs), where little research has been done to date. Focus on CTCs might allow capture of intact cancer cells that can be used for myriad of biomarker testing that cannot be done on plasma ctDNA.

“Far too many people, at younger and younger ages, are diagnosed with fatal cancers, often after living with a digestive disease. Despite its prevalence, colon cancer research is grossly underfunded. CA CURE quickly puts vital research dollars in the hands of leading scientists.”
Yekaterina Chudnovsky, Board Chair
“The Translational Core is used by nearly every faculty member in GI. We can follow patients long-term and study the natural history of disease outcomes, to understand medical therapies, and gain mechanistic insights into why people develop digestive diseases.”

Joel Pekow, MD, Director, Translational Core

WE EDUCATED OUR CONSTITUENTS on disease management and scientific breakthroughs.

WE SUPPORTED THE NEXT GENERATION OF GI RESEARCHERS by supporting physicians and scientists early in their careers through the Associate Board Young Investigator Awards program.

WE SUSTAINED ESSENTIAL INFRASTRUCTURE FOR PHYSICIAN-SCIENTISTS WORKING IN THE LAB TOWARDS BETTER PATIENT CARE AND CURES.

Provided critical capital funding, which is almost impossible to get from traditional medical research funders, for best-in-class facilities and state-of-the-art equipment.

VISCERAL: LISTEN TO YOUR GUT PODCAST

Featuring the latest research updates and treatment options on specific digestive diseases. Episodes are presented by the physician-scientists and experts at the University of Chicago Medicine.

MOVING THE NEEDLE

On March 8, 2023, guests had an opportunity to learn about GI Research Foundation’s funded research projects both in-person and virtually.

TRANSLATIONAL CORE AT UCHICAGO MEDICINE

An innovative tissue bank that maintains a large registry of over 35,000 biospecimens drawn from over 10,000 patients seen at subspecialty clinics for IBD, liver disease, pancreatic disease, esophageal disorders, hereditary GI cancers, celiac disease, liver tumors, and obesity. Unique to the UChicago Medicine Digestive Diseases Center, it is a means of optimizing data collection not just for one study, but for many and helps to facilitate interdisciplinary research across otherwise siloed areas of expertise.

SMALL ANIMAL COLONOSCOPY SYSTEM

$106,446

Colonoscopy with biopsy is the gold standard for diagnosis and assessment of bowel injury and disease progression. The Storz Coloview Small Animal Colonoscopy System is integral to supporting the ongoing research of several University of Chicago Medicine laboratories, providing high-resolution imagining and collection of samples from murine subjects.

ALAN HUTCHINSON, MD, PHD

$10,000

Interaction of Body Composition and the Microbiome in Liver Disease

ALEXANDER LITTLE, PHD

$10,000

Bacterial Anaerobic Respiration and Rational Bile Acid Design

DEEPINDER KAUR, PHD

$10,000

Role of Akkermansia Muciniphila in Mucosal Healing—a Potential Microbial Therapeutic Approach to IBD

GREGORY MALNASSY, PHD

$10,000

Targeting the Unfolded Protein Response to Enhance Pancreatic Neuroendocrine Tumors (PanNETs) Radiosensitivity

GIRF FISCAL YEAR 2023 IMPACT REPORT
YOU HELPED CELEBRATE OUR IMPACT

THE 2023 GI RESEARCH FOUNDATION ANNUAL BALL RAISED MORE THAN $1.2 MILLION FOR RESEARCH TO TRANSFORM LIVES ALL OVER THE WORLD.

On Saturday, May 20, 2023, the GI Research Foundation Annual Ball celebrated 62 years of supporting research to cure, treat, and prevent digestive diseases. More than 400 attendees gathered at The Geraghty in Chicago for cocktails, appetizers, dinner, and a performance from Las Vegas headliner, master illusionist Mat Franco. The evening featured a mission-centered program—with funding highlights from an extraordinary year and the Joseph B. Kirsner Award presentation to Eugene B. Chang, MD.
The GI Research Foundation proudly presented the Larry A. Pogofsky All-Star Challenge on Monday, August 7, 2023, at Bryn Mawr Country Club in Lincolnwood, Illinois. A full field of golfers alongside celebrity athletes enjoyed a day on the greens honoring Larry’s love for sports and continuing his legacy of funding critical medical research. The outing raised more than $235,000 for groundbreaking digestive diseases research.
FINANCIAL OVERVIEW 2023

96% of support went directly to research grants and educational programs.

Over $20 Million was invested in research.

STATEMENT OF ACTIVITY
Year End June 30, 2023

REVENUE AND SUPPORT
- Fundraising - special events: $14,939,19
- Donations - restricted: $18,696,971
- Donations - unrestricted: $380,248
- Bequests - unrestricted: $6,667
- Interest and dividend income: $306,598
- Realized gain on investments: $821,695
- Unrealized loss on investments: ($584,743)

TOTAL REVENUE AND SUPPORT: $21,121,355

EXPENSES
- PROGRAMS AND SERVICES:
  - Grant awards: $20,219,690
  - Salaries and benefits: $323,730
  - Venues for educational programming: $119,962
  - Podcast, newsletter, and education: $28,525
  - Professional fees: $1,500
  - Program office expenses: $25,444
  - Travel and meetings: $22,200

TOTAL PROGRAMS AND SERVICES: $20,741,051

- GENERAL AND ADMINISTRATION:
  - Salaries and benefits: $107,910
  - Professional fees: $12,565
  - Rent and office expenses: $11,299
  - Meetings: $4,001

TOTAL GENERAL AND ADMINISTRATION: $135,775

- FUNDRAISING:
  - Fundraising event expenses: $396,858
  - Salaries and benefits: $107,910
  - Donation processing fees: $15,449
  - Postage and office expenses: $8,481
  - Professional fees: $9,800

TOTAL FUNDRAISING: $538,498

EXPENSES TOTAL: $21,415,324

CHANGE IN NET ASSETS
- ($293,969)

NET ASSETS, BEGINNING: $4,164,696

NET ASSETS, ENDING: $3,870,727

STATEMENT OF FINANCIAL POSITION
Year End June 30, 2023

ASSETS
- CURRENT ASSETS:
  - Cash and cash equivalents: $343,396
  - Investments: $12,318,916
  - Accounts receivable: $52,881
  - Prepaid expenses: $8,106

TOTAL CURRENT ASSETS: $12,723,299

- NET ASSETS:
  - Without donor restrictions: $3,870,727
  - With donor restrictions: -

TOTAL CURRENT LIABILITIES: $8,852,572

LIABILITIES AND NET ASSETS
- CURRENT LIABILITIES:
  - Accounts payable: $8,782,517
  - Accrued expenses: $7,625
  - Deferred revenue: $62,430

TOTAL CURRENT LIABILITIES: $8,852,572

- WITHOUT DONOR RESTRICTIONS:
  - $3,870,727

TOTAL LIABILITIES AND NET ASSETS: $12,723,299
2023 BOARD OF DIRECTORS

KATHRYN KARMIN SHAFER  
PRESIDENT

YEKATERINA CHUDNOVSKY*  
CHAIRPERSON

HOWARD A. GRILL*  
VICE PRESIDENT OF FINANCE/TREASURER

BRAD PETERSON  
SECRETARY

MARK A. WALDECK  
VICE PRESIDENT OF MARKETING

BENJAMIN POGOFSKY  
VICE PRESIDENT OF BOARD DEVELOPMENT

BIANA LANSON, MD  
VICE PRESIDENT OF RESEARCH GRANTMAKING

MURRAY ALSCHER  
SCOTT ATTAR  
ERIC BERLIN*  
MICHAEL P. COGAN*  
RUSSELL D. COHEN, MD  
STEVEN R. DAVIDSON*  
JEFFREY A. FINE  
DANNY GOLDBERG  
PETER D. GOLDMAN  
HEIDI HENDERSON  
KARYN HURWICH  
MATTHEW LEBENSON  
JONATHAN MEREL  
BENJAMIN S. RIBACK  
SEYMOUR TAXMAN

SCIENTIFIC ADVISORS

DAVID T. RUBIN, MD  
CHIEF, SECTION OF GASTROENTEROLOGY,  
HEPATOLOGY AND NUTRITION  
UNIVERSITY OF CHICAGO MEDICINE

EUGENE B. CHANG, MD  
MARTIN BOYER PROFESSOR OF MEDICINE  
UNIVERSITY OF CHICAGO MEDICINE

MICHAEL R. CHARLTON, MBBS  
DIRECTOR, CENTER FOR LIVER DISEASES  
CO-DIRECTOR, TRANSPLANT INSTITUTE  
UNIVERSITY OF CHICAGO MEDICINE

ASSOCIATE BOARD

DANNY GOLDBERG, PRESIDENT  
ROB BEACH  
KATIE BRYAN  
COURTNEY CEBULA  
KATHLEEN CIPOLLA  
NOA KRUGLIAK CLEVELAND, MD  
KURT DZIAMA  
RACHEL EAGLE  
JACLYN HANLEY  
CARLY HENNIG  
JORDAN HIRSH  
JOAN LINES  
TREVOR LONG  
JACQUELINE LOPEZ  
DEJAN MICIC, MD  
MARKO MILOSEVIC  
SHEETAL SHAH  
CARLI THOMAS  
LOGAN TURBAN  
KATHERINE WALDECK  
MORGAN WALDECK

ASSOCIATE BOARD ADVISORS

SUSHILA DALAL, MD,  
MEDICAL ADVISOR  
ASSISTANT PROFESSOR,  
UNIVERSITY OF CHICAGO MEDICINE

ASHLEY SIDEBOTTOM, PHD,  
SCIENTIFIC ADVISOR  
METABOLIC PLATFORM DIRECTOR,  
DFI-HMMF, UNIVERSITY OF CHICAGO MEDICINE

ADVISORY COUNCIL

RONALD BORDEN  
DAVID A. RUBIN  
GARY SINGER  
AMY TARA KOCH  
B.H. GERALD ROGERS, MD  
SAUL RUDO  
AARON ROSDAL  
SPENCER G. SACHS

STAFF

DEBORAH BARNARD  
DIRECTOR OF MAJOR GIFTS

DEBORAH BRILL  
DEVELOPMENT AND OPERATIONS ASSISTANT

JACKIE CASEY  
EXECUTIVE DIRECTOR

ALLISON THIELEN  
FINANCE AND OPERATIONS MANAGER

BRITTANY ZELWIN  
FUNDRAISING OFFICER

* PAST PRESIDENT